FREE Stock Alerts By Email!
OTCPicks.com Stocks to Watch for Wednesday, November 25th
MBRK,
VSYM,
ARSC,
NEXM,
SCLD,
IMDS Our Stocks to Watch tomorrow include MiddleBrook Pharmaceuticals Inc.
(Nasdaq:
MBRK), View Systems Inc. (OTCBB:
VSYM), American Security
Resources Corp. (OTC:
ARSC), NexMed Inc. (Nasdaq:
NEXM), SteelCloud Inc.
(Nasdaq:
SCLD) and Imaging Diagnostic Systems Inc. (OTCBB:
IMDS).
MIDDLEBROOK PHARMACEUTICALS (NASDAQ:
MBRK)
"Up 128.57% on Tuesday"
Detailed Quote:
MiddleBrook Pharmaceuticals, Inc. develops and commercializes
anti-infective drug products for the treatment of infectious diseases. It
develops a proprietary, once-a-day pulsatile delivery technology called
PULSYS. The company is developing anti-infective drugs based on its novel
biological finding that bacteria exposed to antibiotics in front- loaded
staccato bursts than those under standard treatment regimens. Its pulsatile
product candidates include MOXATAG, based on the antibiotic amoxicillin,
for the treatment of pharyngitis/tonsillitis (strep throat) for adults and
pediatric patients age 12 and older; and Keflex PULSYS product candidate,
based on the antibiotic cephalexin, which is in Phase I clinical trials for
skin and skin structure infections. In addition, MiddleBrook
Pharmaceuticals sells its Keflex products in both capsule and powder
formulations for the treatment of skin and skin structure infections, and
upper respiratory tract infections primarily through pharmaceutical
distributors and wholesalers to physicians, hospitals, and pharmacies in
the United States. The company was founded in 1999. It was formerly known
as Advancis Pharmaceutical Corporation and changed its name to MiddleBrook
Pharmaceuticals, Inc. in 2007. MiddleBrook Pharmaceuticals is headquartered
in Germantown, Maryland.
MBRK News:
November 5 - MiddleBrook Pharmaceuticals Reports Third Quarter 2009
Results
Solid 3Q Market Share Gains for MOXATAG; The Height of Strep Throat
Season Approaches
Highlights
* MiddleBrook implemented a $20 maximum co-pay program for MOXATAG. (July
2009)
* MiddleBrook completed a realignment of its field sales force and reduced
its corporate staff for an estimated $15 million in annualized expense
savings. (Sept. 2009)
* Approximately 70,000 MOXATAG prescriptions were filled between March 16,
2009, and Oct. 23, 2009, according to IMS Health National Prescription
Audit data.
MiddleBrook Pharmaceuticals, Inc. (Nasdaq:
MBRK) announced its financial
and operational results for the quarter ended Sept. 30, 2009.
MOXATAG tripled its share of the oral-solid penicillin-class antibiotic
market during the 2009 third quarter, said MiddleBrook President and CEO
John Thievon. With the height of the strep throat season approaching in
the first calendar quarter of 2010, we believe our nationwide sales and
marketing campaign will continue to increase awareness of MOXATAG and drive
significant market share and prescription growth over the coming
months.
Third Quarter 2009 Financial Results
MiddleBrook reported third quarter 2009 net revenue of $1.1 million,
compared to net revenue of $2.3 million in the third quarter of 2008. Net
sales of MOXATAG (extended-release amoxicillin) Tablets, 775 mg, totaled
$(0.6) million for the 2009 third quarter and were negatively impacted by a
$1.3 million one-time cumulative adjustment related to the July 2009
implementation of the MOXATAG $20 maximum co-pay program. The $1.3 million
adjustment applies to MOXATAG inventory sold into the channel before the
third quarter of 2009. Net sales for the KEFLEX (cephalexin, USP)
franchise totaled $1.7 million in the third quarter of 2009.
Net loss was $17.0 million for the 2009 third quarter, compared to a net
loss of $12.5 million attributable to MiddleBrook in the third quarter of
2008. Net loss per share during the third quarter of 2009 was $0.20,
compared to a net loss per share of $0.19 in the prior-year third quarter.
MiddleBrook reported cost of goods sold in the amount of $0.5 million for
the 2009 third quarter, compared to $0.3 million in the prior-year period.
Research and development (R&D) expense in the third quarter of 2009 was
$1.4 million, compared to third quarter 2008 R&D expense of $6.9 million.
Selling, general and administrative expense was $16.2 million in the third
quarter of 2009, compared to $7.0 million in the prior-year period.
As of Sept. 30, 2009, MiddleBrooks cash, cash equivalents, and
marketable securities totaled $28.4 million, compared to $74.7 million as
of Dec. 31, 2008.
Outlook
MiddleBrook is narrowing its 2009 annual revenue guidance and expense
estimate and is providing a total operating expense estimate for 2010.
Combined 2009 net sales for MOXATAG and KEFLEX are now expected to range
between $16 and $18 million. Total 2009 operating expenses are anticipated
to range between $75 and $78 million. MiddleBrook estimates that its total
2010 operating expenses will range between $65 and $70 million. The Company
anticipates the need to raise additional capital to fund operations through
2010.
VIEW SYSTEMS INCORPORATED (OTCBB:
VSYM)
"Up 60.00% on Tuesday"
Detailed Quote:
View Systems, Inc. manufactures and installs weapons detection
identification systems, video management platforms and tele-data
communication networks targeted towards correctional facilities, schools,
courthouses, government agencies, event and sports venues, and commercial
businesses.
VSYM News:
November 24 - View Systems` Product Partner, Belcom, Announces Orders From
Saudi Arabia, India, Bangladesh and the UAE
View Systems, Inc. (OTCBB:
VSYM), a security and tele-data solutions
provider, announced that the company`s leading authorized and exclusive
international dealer and business partner, Belcom, a Belhasa International
Company, has received a second round of orders for ViewScan units and other
View Systems products from Saudi Arabia, Bangladesh, India and the United
Arab Emirates. The orders have been placed by a mixture of government and
corporate clientele.
ViewScan is fast becoming the choice screening system, both domestically
and internationally. It`s a computer-based system that can scan up to 1200
people per hour. As a person passes through the portal, a photograph is
taken and stored on the laptop computer that comes with the unit. Threat
objects are visually located on the computer screen and an audible alert
can be set to sound. The ViewScan produces no harmful emissions so it`s
safe for everyone.
Belcom is an authorized and exclusive international dealer and business
partner of View Systems. Belcom represents View Systems` products in the
Middle East, Africa, Saudi Arabia, Kuwait, Qatar, Bahrain, UAE, Oman,
Jordan, Iraq, India, Pakistan, Bangladesh and Yemen. Belcom is a subsidiary
of the Belhasa Group of Companies, a trusted security and services firm
with proven performance throughout the Middle East and Africa. Belcom is
one of the fastest growing security services companies in the Middle East
today. Belcom`s corporate headquarters is based in Dubai, UAE with field
offices located throughout the
MENA region. (Source: www.belcom.ae).
Belcom`s team has an impressive track record of successfully completing
projects for clients regardless of location, specifically with ViewScan
units currently placed in Saudi Arabia, Bahrain, UAE, India and Pakistan.
Gautham Belthur, General Manager of Belcom, states, "There is a phenomenal
amount of interest from various sectors for the ViewScan units. We have
been receiving inquiries from all over the Middle East, Africa and Asia
regions. The most pleasing fact is that not only sensitive government
institutions, but also corporate entities, prefer the ViewScan over
traditional metal detectors for their security needs. The product has
received a huge thumbs-up from all our clients and they are delighted to
see top-notch technology and service from Belcom. Armed with such a
positive initial response, we expect to move quantities of more than 200
units by the end of 2010."
AMERICAN SECURITY RESOURCES CORPORATION (OTCBB:
ARSC)
"Up 50.00% on Tuesday"
Detailed Quote:
ARSC is a holding company actively seeking to acquire companies and
technologies that will advance the development of alternative energies.
ARSC, through its Hydra subsidiary, has developed high volume, mass
producible hydrogen fuel cells. Its American Hydrogen Corp. subsidiary is
developing methods to inexpensively formulate hydrogen.
ARSC News:
November 24 - Hydra to Receive Three More Patents
The Buskop Law Group (www.buskoplaw.com) has notified Hydra Fuel Cell
Corporation, a wholly owned subsidiary of American Security Resources
Corporation (OTC:
ARSC), that three more of its original patent
applications are completely or partially approved and ready for issue
subject to final patent office action.
Buskop Law Group is patent counsel for American Security Resources
Corporation and its subsidiary, Hydra Fuel Cell Corporation
(www.hydrafuelcell.com).
Bob Farr, President and COO of
ARSC, stated, We are pleased that the US
Patent Office has recognized the unique quality of our original fuel cell
development. Our science has advanced significantly from that time,
however, and is far different from the science in these patents.
ABOUT BUSKOP LAW GROUP
Buskop Law Group is one of Houstons leading patent firms. Their
services include patent drafting and issuance, trademark application and
issuance, copyright filings, strategic advice on patent portfolios and
foreign patent and trademark filings. Buskop Law Group is affiliated with a
global network of patent and trademark firms in over 20 countries.
NEXMED INCORPORATED (NASDAQ:
NEXM)
"Up 31.63% on Tuesday"
Detailed Quote:
NexMeds pipeline includes its innovative topical onychomycosis
treatment, which is licensed to Novartis for global development, a late
stage alprostadil treatment for erectile dysfunction, a Phase 2 treatment
for female sexual arousal disorder, and an early stage treatment for
psoriasis.
NEXM News:
November 23 - NexMed, Inc. to Acquire Bio-Quant, Inc.
* Cash Flow Positive, Growing Business Provides NexMed with Pre-clinical
Capabilities, Added Licensing Expertise and Critical Mass
* Transaction May Enable Continued NASDAQ Listing
NexMed, Inc. (Nasdaq:
NEXM), a developer of products based on the NexACT
technology, announced that it has entered into a definitive agreement to
acquire Bio-Quant, Inc., a revenue generating privately-held leading
research organization for in vitro and in vivo contract drug discovery and
pre-clinical development services, headquartered in San Diego, CA. Upon
closing of the transaction, which is expected before the end of the year,
Bio-Quant will become a wholly-owned subsidiary of NexMed. Bassam Damaj,
Ph.D., co-founder, current Chief Executive Officer and Chief Scientific
Officer of Bio-Quant, will become Chief Executive Officer of NexMed,
replacing Vivian Liu, who will transition to the role of Executive Vice
President and, in that capacity, Ms. Liu will continue to be responsible
for leading the business development and licensing efforts for NexMeds
clinical programs. Mark Westgate will remain as NexMeds Chief Financial
Officer. The Board will be composed of three Bio-Quant nominees and four
NexMed nominees, and Ms. Liu is expected to be appointed as Chairman of the
Board.
The agreement provides for NexMeds issuance of 4,000,000 unregistered
shares of its common stock to the Bio-Quant shareholders and a promissory
note (the Note) in the amount of approximately $12.1 million due on
December 31, 2010. NexMed can elect to pay all or any portion of the Note
by issuing its common stock. Such repayment in common stock is contingent
upon NexMed shareholder approval. As a condition to closing, there will be
a Bio-Quant shareholders meeting. Certain key shareholders of Bio-Quant
have agreed to vote in favor of the transaction.
Commenting on todays news, Ms. Liu stated, We look forward to
welcoming the Bio-Quant team as a NexMed subsidiary. Through this
transaction, NexMed acquires a revenue generating, cash flow positive
business which has grown over 250% in the past five years and is continuing
to grow at present. Moreover, we will gain preclinical capabilities, add
valuable licensing expertise and be able to leverage Bio-Quants existing
relationships with key pharmaceutical companies all of which will aid
in the continued development and the ultimate commercialization of our
products under development.
Dr. Damaj, noted, We are delighted to become part of NexMed, a company
with a novel technology and innovative products which we believe can be
better monetized and generate value for our shareholders. While continuing
our normal course of business as a leading CRO, we will be adding Our
established and growing business, resources, and expertise to NexMed, which
should allow NexMed to continue its business development in a more rapid
and efficient manner.
Mark Westgate added, The acquisition of Bio-Quant was an integral part
of our compliance plan presented to the NASDAQ Listing Qualification Panel
(the Panel) on Thursday, November 12, 2009. We are hopeful that the
signing of this agreement will give the Panel further confidence that we
will regain and maintain compliance with all applicable continued listing
requirements. While we have yet to receive a decision from the Panel, we
are optimistic that the Panel will continue our listing pending the
implementation of our plan.
FTN Equity Capital Markets Corp., in New York City, has served as
NexMeds financial advisor in the structuring and negotiations of this
transaction.
ABOUT BIO-
QUANTFounded in 1999, Bio-Quant is the largest specialty CRO based in San Diego
and is one of the industry`s most experienced CROs for in vitro and in vivo
pharmacology services and research models specializing in oncology,
inflammation, immunology, and metabolic diseases, including diabetes.
STEELCLOUD INCORPORATED (NASDAQ:
SCLD)
"Up 31.91% on Tuesday"
Detailed Quote:
SteelCloud is a developer and manufacturer of compliance based technology
solutions. The Company designs and manufactures specialized servers and
appliances for federal integrators, software vendors and volume users. For
both the government and commercial markets the Company delivers integration
services and software focused on risk management and network management
solutions. The Company`s ISO 9001:2000 certified Quality Management System
provides procedures for continuous quality improvement in all aspects of
its business. Over its 20-year history, the Company has won numerous awards
for technical excellence and customer satisfaction.
SCLD News:
November 24 - SteelCloud to Offer a Hosted BlackBerry Enterprise Server
Solution Including License Administration to International Hosting Service
Providers
SteelCloud, Inc. (Nasdaq:
SCLD), a leading developer of mobility computing
appliance solutions announced that it has signed a new agreement with
Research In Motion ("RIM"), enabling it to offer a complete Hosted
BlackBerry Enterprise Server solution that includes license administration
to hosting service providers around the world. These licenses will enable
hosting service providers to offer a hosted BlackBerry service to their
customers.
The Company believes that it will begin to recognize revenue from hosting
service providers under this agreement in the current quarter.
Additionally, SteelCloud, as a BlackBerry Alliance Elite Member, is a
sponsor at the BlackBerry
EMEA Alliance Summit 2009 being held in Rome on
November 25th-27th. This summit is a gathering of BlackBerry Alliance
Program members from Europe, Africa, and the Middle East.
"SteelCloud has been working over the last six months to ensure that we
will provide the international hosting service provider community with the
very best service and license administration for their BlackBerry
Enterprise Server software," said Brian Hajost, SteelCloud`s President and
CEO. "We have received enthusiastic interest from hosting service providers
around the world and look forward to offering them both licensing support
and the SteelWorks appliance as an attractive vehicle for them to migrate
to the new BlackBerry Enterprise Server v5.0."
IMAGING DIAGNOSTIC SYSTEMS (OTCBB:
IMDS)
"Up 32.13% on Tuesday"
Detailed Quote:
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging
device to aid in the detection and management of breast cancer. The
CTLMsystem is a breast imaging system that utilizes patented continuous wave
laser technology and computer algorithms to create 3-D images of the
breast. The procedure is non-invasive, painless, and does not expose the
patient to ionizing radiation or painful breast compression. CT Laser
Mammography (
CTLM) is designed to be used in conjunction with
mammography. It reveals information about blood distribution in the breast
and may visualize the process of angiogenesis, which usually accompanies
tumor growth. The Company is currently engaged in collecting clinical data
to support the Premarket approval application for marketing clearance in
the U.S. The FDA has determined that the Companys clinical study is a
non-significant risk (NSR) investigational device study under 812.3(m) of
the investigational device exemptions (IDE) regulation (21 CFR 812). The
CTLM system is limited by United States Federal Law to investigational use
only in the United States.
IMDS News:
October 14 - Emerging Stock Report Initiates Independent Research Coverage
On Imaging Diagnostic Systems, Inc.
Emerging Stock Report, a leading provider of sector specific independent
investment research, has initiated coverage on Imaging Diagnostic Systems,
Inc. (OTCBB:
IMDS). Emerging Stock Report is currently offering a
complimentary trial subscription. To view its research go to
www.emergingstockreport.com.
OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078,
Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address
is being protected from spam bots, you need Javascript enabled to view it.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS
REPORT. We are not registered as a securities broker-dealer or an
investment adviser either with the U.S. Securities and Exchange Commission
(the "SEC") or with any state securities regulatory authority. We are
neither licensed nor qualified to provide investment advice. OTCPicks.com
makes no recommendation that the purchase of securities of companies
profiled in this web site is suitable or advisable for any person or that
an investment such securities will be profitable. In general, given the
nature of the companies profiled and the lack of an active trading market
for their securities, investing in such securities is highly speculative
and carries a high degree of risk. You are receiving this email because you
have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial
advertisement and is not intended to be investment advice. The report is
not provided to any particular individual with a view toward their
individual circumstances. The information contained in our report is not an
offer to buy or sell securities. We distribute opinions, comments and
information free of charge exclusively to individuals who wish to receive
them.
Our newsletter and website have been prepared for informational purposes
only and are not intended to be used as a complete source of information on
any particular company. An individual should never invest in the securities
of any company profiled based solely on information contained in our
reports. Individuals should assume that all information contained in the
report about profiled companies is not trustworthy unless verified by their
own independent research.
Any individual who chooses to invest in any securities should do so with
caution. Investing in securities is speculative and carries a high degree
of risk; you may lose some or all of the money that is invested. Always
research your own investments and consult with a registered investment
advisor or licensed stockbroker before investing.
Information contained in our report will contain "forward looking
statements" as defined under Section 27A of the Securities Act of 1933 and
Section 21B of the Securities Exchange Act of 1934. Subscribers are
cautioned not to place undue reliance upon these forward-looking
statements. These forward-looking statements are subject to a number of
known and unknown risks and uncertainties outside of our control that could
cause actual operations or results to differ materially from those
anticipated. Factors that could affect performance include, but are not
limited to, those factors that are discussed in each profiled company`s
most recent reports or registration statements filed with the SEC. You
should consider these factors in evaluating the forward-looking statements
included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are
profiled. However, we do not provide any assurance as to the accuracy or
completeness of the information provided, including information regarding a
profiled company`s plans or ability to effect any planned or proposed
actions. We have no first-hand knowledge of any profiled company`s
operations and therefore cannot comment on their capabilities, intent,
resources, nor experience and we make no attempt to do so. Statistical
information, dollar amounts, and market size data was provided by the
subject company and related public information sources which we believe to
be reliable but we cannot guarantee the accuracy of the information. To the
fullest extent of the law, we will not be liable to any person or entity
for the quality, accuracy, completeness, reliability, or timeliness of the
information provided in the report, or for any direct, indirect,
consequential, incidental, special or punitive damages that may arise out
of the use of information we provide to any person or entity (including,
but not limited to, lost profits, loss of opportunities, trading losses,
and damages that may result from any inaccuracy or incompleteness of this
information). We encourage you to invest carefully and read investment
information available at the websites of the SEC at
FINRA at
Disclosure: OTCPicks.com has not been compensated by any of the companies
covered in this release.
See OTC Picks's website for full disclaimer. OTC Picks may have received compensation for stock picks.
home
